systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-135Research ArticleСТАТЬИARTICLESЧем лучше осуществить блокаду ренин-ангиотензин-альдостероновой системыДрапкинаО. М.noemail@neicon.ruКлиника пропедевтики внутренних болезней ММА им. И.М.СеченоваRussian Federation200823122022523640Copyright © Драпкина О.М., 20222022Драпкина О.М.Драпкина О.М.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/135ReferencesEriksson U, Danilczyk U, Penninger JM. Just the beginning: novel functions for angiotensin-converting enzymes. Curr Biol 2002; 12 (21): R745-52.Eriksson U, Danilczyk U, Penninger JM. Just the beginning: novel functions for angiotensin-converting enzymes. Curr Biol 2002; 12 (21): R745-52.Ивашкин В.Т., Драпкина О.М. Клиническое значение оксида азота и белков теплового шока. М., 2001.Ивашкин В.Т., Драпкина О.М. Клиническое значение оксида азота и белков теплового шока. М., 2001.Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Ингибиторы ангиотензинпревращающего фермента в лечении сердечно-сосудистых заболеваний (квинаприл и эндотелиальная дисфункция). М.: ООО "Инсайт полиграфик", 2002.Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Ингибиторы ангиотензинпревращающего фермента в лечении сердечно-сосудистых заболеваний (квинаприл и эндотелиальная дисфункция). М.: ООО "Инсайт полиграфик", 2002.Филлипс П.А., Джонстон С.И. Гормоны и почки. Руководство по нефрологии. Под ред. Дж.А.Витворт, Дж.Р.Лоренса. М.: Медицина, 2000; с. 45-58.Филлипс П.А., Джонстон С.И. Гормоны и почки. Руководство по нефрологии. Под ред. Дж.А.Витворт, Дж.Р.Лоренса. М.: Медицина, 2000; с. 45-58.Burnier M. Angiotensin II Type 1 Receptor Blockers. Circulation 2001; 103: 904-12.Burnier M. Angiotensin II Type 1 Receptor Blockers. Circulation 2001; 103: 904-12.Jorde UP, Ennezat PV, Lisker J et al. Maximally Recommended Doses of Angiotensin-Converting Enzyme (ACE) Inhibitors Do Not Completely Prevent ACE-Madiated Formation of Angiotensin II in Chronic Heart Failure. Circulation 2000; 101: 844-6.Jorde UP, Ennezat PV, Lisker J et al. Maximally Recommended Doses of Angiotensin-Converting Enzyme (ACE) Inhibitors Do Not Completely Prevent ACE-Madiated Formation of Angiotensin II in Chronic Heart Failure. Circulation 2000; 101: 844-6.Julius S et al. Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker. The TROPHY study. N Engl J Med 2006; 354: 1685-97.Julius S et al. Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker. The TROPHY study. N Engl J Med 2006; 354: 1685-97.Swedberg K, Pfeffer M, Granger C et al and CHARM-programme investigators. Candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail 1999; 5: 276-82.Swedberg K, Pfeffer M, Granger C et al and CHARM-programme investigators. Candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail 1999; 5: 276-82.Dubrey S. Angiotensin II receptor antagonists in the treatment of heart failure: background to and design of the CHARM study. Brit J Cardiol 2002; 9: 280-6.Dubrey S. Angiotensin II receptor antagonists in the treatment of heart failure: background to and design of the CHARM study. Brit J Cardiol 2002; 9: 280-6.Pfeffer M, Swedberg K, Granger C et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet 2003; 362: 759-66.Pfeffer M, Swedberg K, Granger C et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet 2003; 362: 759-66.Lindholm LH, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive treatmen and Lipid Profile In a North of Sweden efficacy Evaluation (ALPINE) study. J Hypertens 2003; 21: 1563-74.Lindholm LH, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive treatmen and Lipid Profile In a North of Sweden efficacy Evaluation (ALPINE) study. J Hypertens 2003; 21: 1563-74.Lithell H, Hansson L, Elmfeldt D et al. The Study of Cognition and Prognosis in the Elderly (SCOPE). J Hypertens 2003; 21: 875-86.Lithell H, Hansson L, Elmfeldt D et al. The Study of Cognition and Prognosis in the Elderly (SCOPE). J Hypertens 2003; 21: 875-86.Lacourciere Y, Asmar R. A comparizon of the efficacy and duration of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood presssure after a missed dose, in truly hypertensive patients. A placebo-controlled, forced titration study. Am J Hipertens 1999; 12:1181-7.Lacourciere Y, Asmar R. A comparizon of the efficacy and duration of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood presssure after a missed dose, in truly hypertensive patients. A placebo-controlled, forced titration study. Am J Hipertens 1999; 12:1181-7.
The authors declare that there are no conflicts of interest present.